News

Open Public Consultation: Updated SRIA for European Water4All Partnership

Published on | 1 year ago

Programmes
Agro-Food, Environment Missions

Open Public Consultation on the updated Strategic Research and Innovation Agenda (SRIA) for the European Water4All partnership.

The SRIA of the Water4All Partnership will be updated in 2025. As part of the update process, a public consultation on the topics of the Water4All SRIA is launched. The primary objective is to gather perspectives from stakeholders on the scientific scope of Water4All, who may be interested in taking part in this process. Given the strong involvement of Flemish R&I actors, your input would be most appreciated.

To participate: follow this link until Wednesday 11 September 2024.

Also relevant: On 12th September the third Water4all call on "Water and Circular Economy" will be open. You can find more information on this call via this link. 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1855 articles available search in articles 

Testimonial

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.